Clinical Trial: A Prospective, Open-Label, Single-Arm Exploratory Study on the Safety and Efficacy of NRT6003 Injection in Combination with Targeted Therapy and Immune Checkpoint Inhibitors in the Treatment of Unresectable Hepatocellular Carcinoma. (China)

China, Sept. 23 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Prospective, Open-Label, Single-Arm Exploratory Study on the Safety and Efficacy of NRT6003 Injection in Combination with Targeted Therapy and Immune Checkpoint Inhibitors in the Treatment of Unresectable Hepatocellular Carcinoma.'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133123

Registration Time: 2026/09/22

Type: Interventional study

Primary Sponsor: West China Hospital of Sichuan University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=344249

Published by HT Digital Content Services with permission from Health Daily Digest....